menu
    • menu
    [{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Therapeutics \/ General Catalyst"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Odyssey Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Terray Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Terray Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Odyssey Therapeutics \/ Terray Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Odyssey Therapeutics

    Menu

    Odyssey Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Terray Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Odyssey And Terray Therapeutics Partner on Transcription Factor Therapies

                            Details : The companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across immune and inflammatory diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Terray Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Odyssey Therapeutics Announces Collaboration for AI-Driven Drug Discovery

                            Details : The companies will collaborate to discover & optimize small molecule medicines against select therapeutic targets by integrating artificial intelligence, machine learning & computational chemistry.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Ascenta Capital

                            Deal Size : $101.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Odyssey Therapeutics Announces $101 Million Series C Financing

                            Details : The proceeds will support the advancement of multiple programs for clinical studies of immunology and oncology therapeutics & several of these molecules have the potential to enter the clinical development in next 12 months.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Ascenta Capital

                            Deal Size : $101.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Odyssey Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : General Catalyst

                            Deal Size : $168.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing

                            Details : The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 13, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : General Catalyst

                            Deal Size : $168.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth